Axel Nogai
Overview
Explore the profile of Axel Nogai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
373
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tranter E, Busch D, Heck C, Blau I, Nogai A, Schiele P, et al.
Front Immunol
. 2025 Feb;
16:1532645.
PMID: 40013147
Introduction: Infections are a major cause of early morbidity and mortality in patients with multiple myeloma (MM) who are characterized by immunodeficiency secondary to disease. However, prospectively collected data on...
2.
Mai E, Nogai A, Lokhorst H, van der Holt B, Zweegman S, Weisel K, et al.
Hemasphere
. 2024 Nov;
8(11):e70052.
PMID: 39569355
No abstract available.
3.
Kruger J, Blau I, Blau O, Bettelli A, Rocchi L, Bocchi M, et al.
Leuk Res
. 2024 Nov;
147:107599.
PMID: 39486120
Multiple myeloma is an aggressive neoplasm of plasma cells. While numerous drugs have gained approval, the absence of established predictive markers for individual drug responses poses a challenge. In this...
4.
Leypoldt L, Tichy D, Besemer B, Hanel M, Raab M, Mann C, et al.
Future Oncol
. 2024 Sep;
20(39):3193-3207.
PMID: 39345094
No abstract available.
5.
Kruger J, Obenaus M, Blau I, Hoser D, Vaegler M, Rauschenbach H, et al.
Haematologica
. 2024 Sep;
110(1):244-250.
PMID: 39279443
No abstract available.
6.
Ramberger E, Sapozhnikova V, Ng Y, Dolnik A, Ziehm M, Popp O, et al.
Nat Cancer
. 2024 Jun;
5(8):1267-1284.
PMID: 38942927
Multiple myeloma (MM) is a plasma cell malignancy of the bone marrow. Despite therapeutic advances, MM remains incurable, and better risk stratification as well as new therapies are therefore highly...
7.
Leypoldt L, Gavriatopoulou M, Besemer B, Salwender H, Raab M, Nogai A, et al.
Cancers (Basel)
. 2023 Sep;
15(18).
PMID: 37760637
Renal function impairment (RI) is a common complication in multiple myeloma (MM). However, limited data exist on the safety and efficacy of anti-MM regimens in patients with severe RI, as...
8.
Leypoldt L, Tichy D, Besemer B, Hanel M, Raab M, Mann C, et al.
J Clin Oncol
. 2023 Sep;
42(1):26-37.
PMID: 37753960
Purpose: The GMMG-CONCEPT trial investigated isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in transplant-eligible (TE) and transplant-noneligible (TNE) patients with newly diagnosed multiple myeloma (NDMM) with exclusively high-risk disease for whom...
9.
Ocio E, Perrot A, Bories P, San-Miguel J, Blau I, Karlin L, et al.
Leukemia
. 2023 Jun;
37(7):1521-1529.
PMID: 37316728
Patients with newly diagnosed multiple myeloma (NDMM) ineligible for autologous stem cell transplantation (ASCT) have lower survival rates and may benefit from frontline regimens that include novel agents. This Phase...
10.
Heynen G, Baumgartner F, Heider M, Patra U, Holz M, Braune J, et al.
Blood Adv
. 2022 Aug;
7(4):469-481.
PMID: 35917568
Proteasome inhibition is a highly effective treatment for multiple myeloma (MM). However, virtually all patients develop proteasome inhibitor resistance, which is associated with a poor prognosis. Hyperactive small ubiquitin-like modifier...